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Insulin-like growth factors (IGFs) are peptide hormones involved
in regulation of cell proliferation, differentiation and apoptosis.
Most IGFs in the circulation originate in the liver. Since IGFs are
regulated by both endocrine and paracrine mechanisms, the action
of IGFs in tissue, however, is determined not only by the circu-
lating levels of IGFs and IGF-binding proteins (IGFBPs), but also
by local production (Jones and Clemmons, 1995). There is a large
interpersonal variability in the circulating concentrations of IGF-I
and IGFBP-3 (a major IGFBP in the circulation) (Juul et al, 1994,
1995). 
Several studies have shown that prostate cancer patients have
higher serum IGFBP-3 levels than healthy males (Cohen et al,
1993; Ho and Baxter, 1997; Wolk et al, 1998; Signorello et al,
1999; Stattin et al, 2000). Some studies have reported that IGF-I
levels were higher in prostate cancer patients than in the control
subjects (Cohen, 1993; Ho and Baxter, 1997; Mantzoros et al,
1997; Chan et al, 1998; Wolk et al, 1998; Djavan et al, 1999;
Signorello et al, 1999; Stattin et al, 2000; Harman et al 2000),
whereas others showed the opposite (Kanety et al, 1993; Finne 
et al, 2000; Kurek et al, 2000). 
To further examine the association of IGF-I with prostate
cancer, we performed a systematic meta-analysis of all the studies
published so far, to determine whether, after controlling for age,
circulating levels of IGF-I are higher in prostate cancer patients
than in control subjects. We also assess the strength of the associa-
tion between circulating IGFBP-3 and prostate cancer. 
MATERIALS AND METHODS 
Selection of studies 
We searched the OVID MEDLINNE database (from January 1966
through February 2001) for articles that had the following text
in the subject heading: ‘Insulin-like growth factor-I’, ‘prostate
neoplasm;’ and in combination with ‘case control studies’ or
‘prospective studies’. We also searched the PubMed database
(from the mid-1960s through February 2001) for literature with
the keywords ‘insulin-like growth factor-I’, ‘prostate neoplasm’,
and in combination with ‘case control studies’ or ‘prospective
studies’. These searches were restricted to the studies in which
IGF-I concentration was measured. We also performed a manual
search of references cited in the published original and review arti-
cles. Two investigators independently reviewed all potentially
relevant articles. Disagreement or uncertainty between two inves-
tigators was resolved by discussion. Inclusion was restricted to
case–control studies and prospective cohort studies published in
English. 
Data abstraction 
Data were independently abstracted in duplicate by 2 investigators
using a standard protocol and data collection form. Disagreements
were resolved by discussion. Characteristics abstracted from the
studies included: the name of first author, location of the study,
year of publication, case definition, control definition and selec-
tion criteria, method of IGF-I and IGFBP-3 measurements,
confounding factors that were controlled for by matching or
adjustment, and mean and standard deviation of IGF-I and IGFBP-
3 in each group. 
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The meta-analysis methods developed by Hedges and Olkin
(1985) were used in our analysis. The following steps were taken
in the analysis specifically. First, weighted mean effect sizes (stan-
dardized mean level difference) and their 95% confidence inter-
vals (CIs) were calculated. A mean effect size is statistically
significant when the CI does not include zero. Second, the homo-
geneity of effect sizes among these studies was determined. Third,
moderator variable analysis was performed to determine whether
effect sizes varied significantly with study characteristics. In this
study, the type of control (healthy male or patient with benign
prostate hyperplasia) and study score (high or low) are the moder-
ator variables. Since sample size varied among the studies, a
correction procedure (Hedges and Olkin, 1994) was applied to the
standardized mean difference to yield unbiased estimates of their
population values. We pooled effect sizes in our analysis using 
a fixed-effect model because statistical power is higher for the
fixed-effect model than for a random-effect model (Rosenthal,
1994). A random-effect model usually generates a more conserva-
tive estimate than a fixed-effect model (DerSimonian and Laird,
1986). The homogeneity of the Hedges’ standardized mean differ-
ence across studies was evaluated by using Hedges’ method
(Hedges and Olkin, 1985). The chi-square test (Prentice and
Thomas, 1986) was used to test homogeneity among studies when
the effect size is taken to be the odds ratio (OR). 
The effects size of standardized mean difference was classified
as small (< 0.2), moderate (0.2–0.5), and large (> 0.5) (Cohen,
1965). For example, a moderate effect size of 0.5 implies that the
score of the average individual in the case group exceeds that of
69% of individuals in the control group (Hedges and Olkin, 1985).
We also used the OR as an alternative measure of the effect size to
evaluate the association between IGF-I and prostate cancer. To
calculate the OR, we converted the estimated effect size (δ ) to a
correlation coefficient (ρ ) using a method of Hedges and Olkin
(1985; Equation 1). Where the ncs is the total number of cases and
nct is the total number of controls. If an effect size is < 0, then a
negative value of the correlation coefficient derived from previous
step was used in the next step. Next, the proportion of cases that
have a higher (greater than the median) IGF-I level (success rate,
0.5 + ρ /2 for case with higher IGF-I level and 0.5–ρ /2 for control
with lower IGF-I level) was derived from the Rosenthal and
Rubin’s criteria (1982). These processes were repeated for the
Hedges standardized mean difference (HSMD) and its 95% CI.
The OR and its 95% CI were estimated from equation 2. The
general variance-based method was used to estimate the summary
measure of OR and its 95% CI (Prentice and Thomas, 1986). 
We also examined the influence of various exclusion criteria on
the overall standardized mean difference of IGF-I and IGFBP-3
between the cases and controls. One of the exclusion criteria was
the use of patients with benign prostatic hyperplasia as controls;
another was small sample size (i.e. total < 100). According to the
central limit theorem, the distribution of effect-size estimates will
be approximately normal if the sample size in each study is large
enough (Daniel, 1999). In our analysis, a number of cases or
controls > 50 were considered a reasonably large sample size for
normal approximation. 
Studies in which the controls consisted entirely of benign
prostatic hyperplasia (BPH) patients or in which the sample size
was < 50 in either case or control groups were classified as a low-
score group. Studies in which the controls consisted entirely of
healthy males and in which sample size was > 50 in both case and
control groups were categorized as a high-score group. Based on
these criteria, seven studies (Cohen et al, 1993; Kanety et al, 1993;
Ho and Baxter, 1997; Baffa et al, 2000; Djavan et al, 1999; Finne
et al, 2000; Khosravi et al, 2001) were classified as low score and
the other 7 as high score. 
In our meta-analysis, the OR for IGF-I was reported first and
followed by IGFBP-3. The estimation of OR by control type was
reported first and followed by study score. For the purpose of
reference, the corresponding Hedges’ standardized mean differ-
ence was also reported where appropriate. 
RESULTS 
A total of 14 studies were found as a result of our literature search,
12 of which reported the mean and standard deviation of IGF-I.
We obtained the mean and standard deviation of IGF-I and
IGFBP-3 directly from the authors of the two studies that did not
report these data (Chan et al, 1998; Harman et al, 2000). The char-
acteristics of the studies are presented in Table 1. Of the 14
case–control studies (two of them nested), 5 were conducted in the
USA, 6 in Europe, and 3 elsewhere. The total number of study
subjects ranged from 19 (Ho and Baxter, 1997) to 665 (Finne 
et al, 2000); the number of cases ranged from 12–210 and the
number of controls ranged from 6–486. IGF-I concentrations were
determined by radioimmunoassay (RIA) in 6 of the 14 studies
(Table 1), while immunoradiometric assay (IRMA) and enzyme-
linked immunoabsorbent assay (ELISA) were used in 4 and 4
studies, respectively. IGFBP-3 was measured using IRMA, RIA,
and ELISA in 3, 2, and 2 of the 9 studies, respectively; in the other
2 studies it was measured by either Western blots or immunofluo-
rometric assay (IFMA). As a confounding factor, age was
controlled in 8 of the 14 studies. 
The mean and standard deviation of IGF-I concentration were
obtained from all 14 studies, but of IGFBP-3 in only 9. Table 2
lists the sample size and mean concentration of IGF-I and IGFBP-
3 in all the studies analysed. The concentration unit for IGF-I was
ng/ml in 13 of the 14 studies and nmol/l in the other study (Kanety
et al, 1993). For IGFBP-3, the unit was ng/ml in 8 of the 9 studies
and unit/ml in 1 study (Cohen et al, 1993). Table 3 lists the
comparison of mean age between the case and control groups.
Four studies did not report mean and standard deviation of age, but
in 3 of the 4 studies, cases and controls were matched on age (± 1
year) (Cohen et al, 1993; Chan et al, 1998; Stattin et al, 2000).
There were no statistically significant differences in mean age
between the cases and controls in 6 studies, though one study
showed a significantly higher mean age in the cases than in
controls (Kanety et al, 1993). 
The overall estimations of the HSMD for IGF-I for all the
studies combined, high-score group, low-score group, studies in
992 R Shi et al 
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Table 1 Characteristics of case–control studies for prostate cancer and IGF-I and IGFBP-3 
Author Year and location Cases Controls Method for IGF- I Method for IGFBP-3 Variables matched/controlled for 
Cohen et al 1993, North Carolina, USA 32 untreated prostate cancer 16 healthy males RIA Western blots age 
Kanety et al 1993, Israel 14 prostate cancer 6 healthy males RIA 
Ho and Baxter 1997, Australia 12 inoperable PC 7 healthy males RIA RIA 
Mantzoros et al 1997, Massachusetts, USA 51 histologically confirmed PC 52 healthy, elderly males RIA age+/–1 
Chan et al* 1998, Maryland, USA 152 confirmed cases 152 healthy males ELISA ELISA age+/–1, smoking, follow-up duration 
Wolk et al 1998, Sweden 210 newly, cytologically and historically  224 biopsy specimens showed no  IRMA IRMA 
confirmed PC evidence of cancer
Djavan et al 1999, Austria 71 prostate cancer 174 benign prostate hyperplasia IRMA 
Signorello et al 1999, Sweden 208 prostate cancer 70 healthy males IRMA IRMA 
Baffa et al 2000, Pennsylvania, USA 57 prostate cancer 39 males ELISA age 
Finne et al 2000, Finland 179 prostate cancer 486 benign controls ELISA IFMA 
Harman et al 2000, Maryland, USA 72 prostate cancer 127 controls RIA RIA age, lengths of follow-ups 
Kurek et al 2000, Germany 171 prostate cancer 67 males RIA age 
Stattin et al 2000, Sweden 149 prostate cancer 298 males IRMA IRMA age+/–1, survey date, residency 
Khosravi et al 2001, Canada 84 prostate cancer 75 benign prostate hyperplasia ELISA ELISA age, 
All are case–control studies, except studies of Chan et al and Harman et al, which is a nested case-referent study. 
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3which controls consisted entirely of healthy males, and studies 
in which controls consisted entirely of patients with BPH, were
0.195, 0.194, 0.197, 0.153 and 0.296, respectively (Table 4). These
HSMD were statistically significant (P < 0.05). The overall esti-
mations of the HSMD for IGFBP-3 in the same groups were 0.111,
0.116, 0.100, 0.123 and 0.083 respectively, being statistically
significant (P < 0.05) for the high-score group and studies in
which controls consisted entirely of healthy males. 
Table 4 also shows the estimated OR and its 95% CI with
respect to IGF-I and IGFBP-3 in each study and in all studies
combined, as well as analyses by the control type and study score.
The OR for IGF-I was > 1.00 in 10 of the 14 studies. An OR
significantly higher than 1.0 was found in 6 studies; 4 studies had
an OR significantly less than 1.0 when comparing high levels IGF-
I with low IGF-I. The overall OR for IGF-I was 1.47 (95% CI
1.27–1.71). There was no homogeneity among the 14 studies 
(χ 2 = 201.1, degree of freedom (df) = 13, P < 0.001). 
When 3 studies that used patients with benign prostatic hyper-
plasia as controls (Djavan et al, 1999; Finne et al, 2000, Khosravi
et al, 2001) were excluded from the OR estimation, the overall OR
declined from 1.47 to 1.36, but remained statistically significant 
(P < 0.01). The homogeneity test showed that the remaining 
11 studies were still not homogeneous with regard to the effect
size (chi-square = 71.03, df = 10, P < 0.01). 
The overall ORs were 1.47 and 1.48 (P < 0.01 for both) for the
high scoring and low-scoring groups respectively. Homogeneity
994 R Shi et al 
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Table 2 Studies reporting IGF-I and IGFBP-3 levels in prostate cancer patients and their controls 
Author and year N
IGF-I 
Cohen et al, 1993 32 151 42 16 138 31 
Kanety et al, 1993 14 17.9* 1.7* 6 24.6* 3.7* 
Ho and Baxter, 1997 12 139 86.6 7 117 44.98 
Mantzoros et al, 1997 51 160.3 68.2 52 124.7 58.6 
Chan et al, 1998 151 269.4 85.7 152 248.9 80.9 
Wolk et al, 1998 210 158.4 53.8 224 147.4 47.6 
Djavan et al, 1999 71 176 26 174 136 23 
Signorello et al, 1999 208 158.2 53.8 70 151.5 53.3 
Baffa et al, 2000 57 124.6 58.2 39 157.5 70.8 
Finne et al, 2000 179 183 66.90 486 194 54.11 
Harman et al, 2000 71 148.3 45.2 126 145.1 50.0 
Kurek et al, 2000 171 158.6 66.5 67 159.1 58.4 
Stattin et al, 2000 149 229 70.27 298 214.4 57.5 
Khosravi et al, 2001 84 126.6 44.82 75 101.2 47.2 
IGFBP-3 
Cohen et al, 1993 36 13.1† 0.8† 18 13.2† 1.8†
Ho and Baxter, 1997 12 2434 270 7 1909 364 
Chan et al, 1998 152 2841.7 757.9 152 2836.3 794.9 
Wolk et al, 1998 210 2668 1037 224 2518 774 
Signorello et al, 1999 208 2664 1041 70 2556 783 
Finne et al, 2000 179 4558 1337.9 486 4526 1234.5 
Harman et al, 2000 71 2800 720 126 2800 760 
Stattin et al, 2000 149 2611 578.1 298 2498.5 539.5 
Khosravi et al, 2001 84 2220 559 75 2070 528 
*nmol/1; †units/ml. 
Table 3 Comparison of mean ages in the case and control groups 
Case(years) Control(years)
Studies N X SD N X SD P-value* 
Cohen et al, 1993 32 –– 16 –– –  
Kanety et al, 1993 14 68.5 3.4 6 56.4 5.9 <0.001 
Ho and Baxter, 1997 12 74.4 6.2 7 68.6 7.1 0.081 
≤ 69 20 21 0.973†
Mantzoros, 1997 (Age group) 70–74 18 17 
≥ 75 14 14 
Chan et al, 1998 152 –– 152 –– –  
Wolk et al, 1998 210 –– 224 –– –  
Djavan et al, 1999 71 65.7 6 174 67.7 9 0.086 
Signorello et al, 1999 208 69.9 6.3 70 70.9 5.5 0.237 
Baffa et al, 2000 57 –– 39 –– –  
Finne et al, 2000 179 62 4.0 486 62.6 4.4 0.111 
Harman et al, 2000 72 64.8 8.9 127 65.7 9.7 0.518 
Kurek et al, 2000 171 66.2 6.1 67 64.5 9.9 0.110 
Stattin et al, 2000 149 59.7 – 298 59.6 ––  
Khosravi et al, 2001 84 64.8 6.2 75 65.6 6.0 0.411 
– not available; *Student t-test; †Pearson chi-square test. 
Case
X (ng/ml) SD (ng/ml)
Control
N X(ng/ml) SD(ng/ml)
BJOC 01-1961 991-996  1/10/01  11:53 am  Page 994was found for the high-scoring group (P = 0.355) but not for the
low-scoring group (P < 0.001). Since high scoring studies were
homogeneous, it might be more reliable to use the overall OR from
these studies to estimate the effect size. For the high-scoring group
the odds of having prostate cancer was 1.47 (95% CI 1.23–1.77),
when comparing men with high IGF-I with those with low IGF-I
levels. 
The overall OR for IGFBP-3 was 1.25 (95% CI 1.058–1.470) in
the 9 studies, which were found to be homogeneous (χ 2 = 13.17,
df = 8, P = 0.106). Of the 9 studies, 2 studies used patients with
BPH as controls (Finne et al, 2000; Khosravi et al, 2001) and when
these were excluded, the overall OR increased from 1.25 to 1.28,
remaining statistically significant (P = 0.015). 
The overall estimation of OR for IGFBP-3 increased slightly
from 1.25 to 1.26 for the high-scoring group (95% CI 1.03–1.54)
and decreased from 1.25 to 1.22 for the low-scoring group (95%
CI 0.91–1.63). The homogeneity test showed that the high score
studies were homogeneous (χ 2 = 2.56, df = 4, P = 0.64), whereas
the low-scoring studies were not (P = 0.012). 
DISCUSSION 
Selection bias may exist in case–control studies, and this bias, if it
existed in the original study, cannot be controlled in meta-analysis.
Out of the 7 studies, 5 (high-scoring group) included in the overall
estimation of OR for IGF-I in the final analysis were matched (by
age) case–control studies; this may lead to either a gain or loss in
study efficiency and introduce selection bias. Matching is a useful
tool for improving study efficiency in terms of the amount of infor-
mation per subject studied, in some but not all situations (Rothman
and Greenland, 1998). There was no homogeneity among the 14
studies included in the initial meta-analysis. Half of the studies
would need to be excluded before we would be able to reach
homogeneity. Even though there were only 7 studies left after
exclusion, we still had a total of 2000 cases and controls in the
final analysis. Overall, circulating IGF-I levels were higher in
prostate cancer patients than in the control subjects, and the differ-
ence was statistically significant. An overall HSMD for IGF-I was
0.194, suggesting that the average level of IGF-I in the case group
exceeds the levels of 57% of individuals in the control group. An
overall OR for IGF-I was 1.47, suggesting that the odds of having
prostate cancer are 1.47 times greater for men with high levels of
IGF-I compared to those with low IGF-I levels. 
Among the studies included in the meta-analysis, there were 3
laboratory methods used for IGF-I measurement and IGF-I
concentrations varied substantially across the studies; in some
cases, the difference was as high as 2-fold (Chan et al, 1998, vs
Kurek et al, 2000). Despite this, it is unlikely that the significant
difference in IGF-I between cases and controls was due to the
different analytic methods for IGF-I, since standard mean differ-
ences were adjusted for variations in measurement methods. 
Though sample size varied significantly between studies, this
was adjusted in the analysis and would not affect the HSMD esti-
mation. 
Because age and other factors were matched between cases and
controls in some of studies, the overall HSMD might not reflect
very well the paired difference between case and control subjects
in this meta-analysis. In our final analysis of IGF-I in high-scoring
group, age as a confounding factor, was controlled for in the 
original study design. Our test showed that the age was not a 
statistical-significant difference in 4 out of the 7 studies (Table 3).
The other 2 studies that did not report mean age for case and
control (Chan et al, 1998; Stattin et al, 2000) were matched by age,
therefore, a difference in IGF-I between the cases and controls
might indeed be present. 
In a case–control study, selection, recall and misclassification
biases may exist. In addition, variation of study design was present
in the 14 studies included in our meta-analysis. However, more
IGF-I and prostate cancer: meta-analysis 995
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Table 4 The individual and combined odds ratios (OR) and its 95% confidence interval (CI) by IGF-I and IGFBP-3 
IGF-I IGFBP-3 
Citation Score Control  N1 N2 HSMD OR 95% CI N1 N2 HSMD OR 95% CI 
Chan et al, 1998 High HM 151 152 0.245 1.63 1.04, 2.54 152 152 0.007 1.01 0.65, 1.59 
Harman et al, 2000 High HM 71 126 0.066 1.14 0.64, 2.03 71 126 0.000 1.00 0.56, 1.79 
Kurek et al, 2000 High HM 171 67 –0.008 0.98 0.56, 1.73 171 67 –––  
Mantzoros, 1997 High HM 51 52 0.556 3.00 1.38, 6.26 51 52 –––  
Signorello et al, 1999 High HM 208 70 0.124 1.28 0.75, 2.20 208 70 0.110 1.25 0.72, 2.13 
Stattin et al, 2000 High HM 149 298 0.235 1.60 1.08, 2.36 149 298 0.203 1.50 1.01, 2.21 
Wolk et al, 1998 High HM 210 224 0.217 1.54 1.06, 2.24 210 224 0.164 1.39 0.95, 2.02 
Baffa et al, 2000 Low HM 57 39 –0.513 0.36 0.17, 0.82 57 39 –– –  
Cohen et al, 1993 Low HM 32 16 0.330 1.93 0.58, 6.09 32 16 – 0.081 0.85 0.26, 2.80 
Ho and Baxter, 1997 Low HM 12 7 0.282 1.75 0.28, 10.04 12 7 1.636 19.82 3.07, 84.69 
Kanety et al, 1993 Low HM 14 6 –2.644 0.01 0.00, 0.08 14 6 –– –  
Djavan et al, 1999 Low BPH 71 174 1.668 20.82 12.64, 33.07 71 174 –– –  
Finne et al, 2000 Low BPH 179 486 –0.190 0.68 0.49, 0.96 179 486 0.025 1.05 0.75, 1.48 
Khosravi et al, 2001 Low BPH 84 75 0.550 2.96 1.59, 5.39 84 75 0.274 1.73 0.92, 3.18 
Combined group High score 1011 989 0.194 1.47 1.23, 1.77 790 870 0.116 1.26 1.03, 1.54 
Low score 449 803 0.197 1.48 1.16, 1.90 307 584 0.100 1.22 0.91, 1.63 
HM 1126 1057 0.153 1.36 1.14, 1.62 834 893 0123 1.28 1.05, 1.56 
BPH 334 735 0.296 1.80 1.37, 2.36 263 561 0.083 1.18 0.87, 1.59 
All studies 1460 1792 0.195 1.476 1.27, 1.71 1097 1454 0.111 1.248 1.06–1.47 
N1: number of cases; N2: number of controls; HSMD: HSMD between cases and controls. The BPH patient and healthy male (HM) served as controls, 
– Not available.
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residency, thereby minimizing bias. 
The lack of control of other risk factors for prostate cancer could
in theory have an effect on the results of our study. For example,
the level of prostate-specific antigen (PSA) could be a confounder
in this study. Men with elevated PSA levels were more likely to be
subsequently diagnosed with prostate cancer than those with
normal PSA levels (Gann et al, 1995; Chan et al, 1998). However,
one study (Chan et al, 1998) showed that the plasma IGF-I level
was strongly related to the risk of prostate cancer even among men
with a normal baseline PSA level. Therefore, it is not likely that
the PSA level has a confounding effect on the association between
IGF-I and prostate cancer. Other confounding factors might exist,
but in the framework of this study, they obviously could not be
evaluated. 
IGF-I is a peptide hormone with strong mitogenic effect on
prostate cancer growth. In this meta-analysis, we found that IGF-I
levels in the blood were higher in prostate cancer patients than in
the controls. High circulating IGF-I may indicate an increase in
prostate cancer risk. It would be interesting to know if serum IGF-
I measurements have a role in the diagnosis of prostate cancer and
a large prospective study would be worthwhile. 
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